These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Jardeleza MS; Miller JW Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692 [TBL] [Abstract][Full Text] [Related]
9. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Chong V Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120 [TBL] [Abstract][Full Text] [Related]
10. [Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept]. Joussen AM Dtsch Med Wochenschr; 2007 Jun; 132(23):1268-72. PubMed ID: 17541869 [TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy in neovascular age-related macular degeneration. Lin RC; Rosenfeld PJ Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677 [No Abstract] [Full Text] [Related]
12. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Nagpal M; Nagpal K; Nagpal PN Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900 [TBL] [Abstract][Full Text] [Related]
13. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? Lim LS; Cheung CMG; Mitchell P; Wong TY Am J Ophthalmol; 2011 Sep; 152(3):329-331. PubMed ID: 21855670 [No Abstract] [Full Text] [Related]
14. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. Giuliari GP; Guel DA; Cortez MA; Cortez RT Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074 [TBL] [Abstract][Full Text] [Related]
15. Paracentesis before intravitreal injection of bevacizumab. Tsui YP; Chiang CC; Tsai YY Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632 [No Abstract] [Full Text] [Related]
16. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Kaiser PK Am J Ophthalmol; 2006 Oct; 142(4):660-8. PubMed ID: 17011860 [TBL] [Abstract][Full Text] [Related]